Ketamine's rapid antidepressant effects have led to a significant increase in off-label psychiatric use, despite the lack of ...

On the heels of FDA’s approval of the Wegovy Pill, Novo Noridsk announced that the oral GLP-1 is now available to patients ...

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, ...

The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

Johnson & Johnson announced that management will hold a fireside chat at 11:15 am, Est, on Monday, January 12, 2026. It will also be presented as a live audio webcast on J&J’s investor relations site.

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024. Novartis ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

The FDA has approved Novo Nordisk’s Wegovy pill to reduce excess body weight, support weight management, and maintain weight ...